protein tyrosine phosphatase non-receptor type 6Genealiases: HCP · HCPH · HPTP1C · PTP-1C · SH-PTP1 · SHP-1
Q-omics provides the consensus-scored PTPN6 profile across patient tissues and cancer cell-line models. PTPN6 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, PTPN6 is differentially expressed in 15, with the highest sampling consensus in KIRC. Additionally, PTPN6 protein abundance shows 26,825 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight BLCA, KIRC, and GBM as cancer lineages where PTPN6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PTPN6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PTPN6 survival associations across molecular data types. PTPN6 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (5) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PTPN6 RNA expression–survival associations across cancer types. High PTPN6 expression shows unfavorable associations in UVM and COAD, but favorable associations in BLCA, SKCM, UCEC and STAD. The BLCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for PTPN6 RNA expression.
This table summarizes PTPN6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for PTPN6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PTPN6 shows lower tumor expression in KICH and LUSC and higher tumor expression in KIRC, HNSC, KIRP and BLCA. The KIRC box plot shows higher PTPN6 RNA expression in tumor versus normal tissue (log2 FC = +1.210, t-test p < 0.001).
This table shows molecular features associated with PTPN6 in patient tissues and cancer cell lines. In patient samples, PTPN6 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, PTPN6 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and UPPER_AERODIGESTIVE_TRACT.
